Studies measuring the proportion of Th17 cells and the serum levels of Th17-related cytokines (IL-17, IL-17A, IL-6, IL-22, IL-23) in CRC and healthy control subjects were included.
Inflammation and pro-inflammatory cytokines produced by Th1 and Th17 cells like IL-6, TNF, IL-17 and IL-23 promote the development and growth of colorectal cancer (CRC).
Elevated IL-23 expression was associated with poor outcome and can be used as a prognostic biomarker for colorectal cancer.J. Surg.Oncol.2017;115:208-212.
Collectively, such findings suggest that IL-23 and/or IL-17A inhibitors should be evaluated for their therapeutic and preventative potential in human cancers, especially in colorectal cancer.
Immunohistochemistry for IL-23p19, IL-23p40, IL-23R and CD8 was performed on a multi-punch tissue microarray of 195 colorectal cancers (cohort 1), matched normal tissue, adenoma and lymph node metastases.
We demonstrated that altered gene expression profiles of IL-12A, IL-12B, IL-23A at mRNA level in CRC monocytes was associated with tumor development and can be attributed to anticancer immune response.